Providence St. Vincent receives 6th Magnet designation

A study for people with GI cancers and two studies for people with advanced and early-stage lung cancer hope to develop better treatment options with the help of immunotherapy.

Providence researchers say comprehensive genomic profiling can be pivotal in identifying gene mutations in a patient and tailoring personalized treatment strategies.

SITC 2023 provides a glimpse into scientific advances and breakthroughs in cancer immunotherapy by researchers from around the world.

Providence Cancer Institute lung cancer expert to present a virtual education talk on lung cancer screening, prevention and latest treatments.

It took a total team effort to make a hospice patient’s dream come true of touching a horse before she died.

Two new studies available at Earle A. Chiles Research Institute, at division of Providence Cancer Institute of Oregon, to evaluate new treatments for triple-negative breast cancer.

Providence Cancer Institute of Oregon, and research director, Earle A. Chiles Research Institute, Walter J. Urba, M.D., Ph.D., receives award for his contributions to science and community.

Providence Heart Institute welcomed patients and their families for the clinic’s third anniversary of its advanced heart failure clinic.

Providence Cancer Institute celebrates Advanced Practice Providers Week from September 25 to 29 and recognizes their important contributions more than 25 clinics and programs.

Providence Cancer Institute of Oregon announces new division director and deputy director of Hematology and Medical Oncology.

The Springs Living has made a generous gift to Providence Foundations of Oregon to establish The Springs Living Regional Chair of Geriatric Medical Education.

For Gynecologic Cancer Awareness Month, Providence Cancer Institute highlights a clinical trial that evaluates the safety and effectiveness of a new oral treatment for grade 1 endometrial cancer.

New trial open at Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, is enrolling patients with advanced or metastatic solid tumors or non-Hodgkin lymphoma.

Beginning Tuesday, Aug. 15, many Alaris infusion pumps at Providence will begin integrating with Epic. See which hospitals and units are affected and what to expect.

Early next year an expansion of our Warrenton Clinic will begin to bring more services to the North Coast community.

Two breast cancer survivors whose stories intersect in a miraculous way, threw the first pitches at the Medford Rogues annual Paint the Park Pink event. Read their story.

In 2021, Dr. Nicole Schmidt was driving around a curve when she saw a car headed straight for her. The crash sent her to a trauma center and started a journey of healing, learning and becoming.

Each year, Providence ministries identify unmet needs and respond with strategic investments in community health. See how we worked to answer the call of our Mission in 2022.

A phase II trial tests FOLFOX or CAPOX versus FOLFIRINOX in patients with locally advanced rectal cancer, and a phase I trial evaluates TBio-4101 in patients with advanced solid tumors.

Final outcomes from a Providence Cancer Institute-sponsored phase Ib trial evaluating pembrolizumab with either weekly paclitaxel or flat-dose capecitabine in treating patients with metastatic TNBC.